Literature DB >> 7528352

Suppression of lymphocyte spontaneous proliferative response by proteolipid protein peptide in patients with HAM/TSP.

T Tabira1, J Inobe, K Nakahara, M Osame, T Yamamura.   

Abstract

To understand the immune mechanism suggested in HTLV-I-associated myelopathy (HAM/TSP), we investigated T cell response to proteolipid protein (PLP). Because of high autologous proliferative response (APR) of peripheral blood mononuclear cells (PBMC) in culture, the lymphocyte proliferation assay was not useful in this disease. Unexpectedly, however, APR was profoundly (70-98%) suppressed in 6 of 9 cases when PLP peptide 105-124 was added in the culture. PLP peptide 85-104 or 145-159 also suppressed APR in a few cases. Time course study showed that the peptide-mediated suppression became apparent after day 4 in culture. The results can be interpreted as that suppressor cells recognizing the PLP peptides were present in the PBMC of HAM/TSP patients and suppressed the APR as the consequence of antigen specific response. This may indicate that a T cell response to certain PLP determinants is involved in the pathomechanism of HAM/TSP at least in part. Molecular mimicry between PLP and HTLV-I may account for the T cell sensitization to PLP in HAM/TSP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528352     DOI: 10.1007/bf00968718

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  21 in total

1.  Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice.

Authors:  J E Green; S H Hinrichs; J Vogel; G Jay
Journal:  Nature       Date:  1989-09-07       Impact factor: 49.962

2.  HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma.

Authors:  K Usuku; S Sonoda; M Osame; S Yashiki; K Takahashi; M Matsumoto; T Sawada; K Tsuji; M Tara; A Igata
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

3.  Chronic experimental allergic encephalomyelitis in guinea pigs induced by proteolipid protein.

Authors:  T Yoshimura; T Kunishita; K Sakai; M Endoh; T Namikawa; T Tabira
Journal:  J Neurol Sci       Date:  1985 May-Jun       Impact factor: 3.181

4.  Autoproliferative and self-reactive T-cell lines from patients with HTLV-I-associated myelopathy.

Authors:  K Usuku; M Nishizawa; N Eiraku; M Osame; T Tabira
Journal:  Tohoku J Exp Med       Date:  1990-11       Impact factor: 1.848

5.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

6.  Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients.

Authors:  C M Pelfrey; J L Trotter; L R Tranquill; H F McFarland
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

7.  Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP).

Authors:  Y Iwasaki
Journal:  J Neurol Sci       Date:  1990-04       Impact factor: 3.181

8.  Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells.

Authors:  M Osame; M Matsumoto; K Usuku; S Izumo; N Ijichi; H Amitani; M Tara; A Igata
Journal:  Ann Neurol       Date:  1987-02       Impact factor: 10.422

9.  A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis.

Authors:  V K Tuohy; Z J Lu; R A Sobel; R A Laursen; M B Lees
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

10.  Cytotoxic and suppressor activities in patients with HTLV-I-associated myelopathy.

Authors:  K Usuku; M Nishizawa; M Osame; T Tabira
Journal:  J Neuroimmunol       Date:  1991-09       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.